Scholarlink

Background <p>In non-small cell lung cancer (NSCLC) patients, antibiotics impair immunotherapy efficacy, while probiotics can enhance it. The relationship between the duration of probiotics and the restoration of immunotherapy efficacy compromised by antibiotics, as well as its potential to enhance immunotherapy outcomes in antibiotic-naive patients, remains unclear. Furthermore, more probiotic types and their mechanisms for improving immunotherapy efficacy need to be identified and elucidated.</p> Methods <p>This multicenter study enrolled wild-type NSCLC patients. Clinicopathological features were recorded, focusing on antibiotic and probiotic use and duration. Baseline fecal and blood samples were collected. Gut microbiota were analyzed via 16S rRNA sequencing, and serum metabolites were analyzed through untargeted metabolomics. Flow cytometry was used to explore potential mechanisms.</p> Results <p>524 wild-type NSCLC patients were enrolled in the study, with fecal samples collected from 22 patients. Patients receiving antibiotics alone exhibited poorer PFS and OS. For those receiving antibiotics, the use of probiotics, regardless of duration, led to improved PFS and OS, which were comparable to those of patients in the No antibiotics + No probiotics group. Among the patients who did not receive antibiotics, those who were treated with probiotics for more than 15 days showed improved PFS. Patients with enriched gut microbiota in <i>un-f-Bifidobacterium</i> and <i>roseburia</i> showed better PFS. The frequency of peripheral Th cells was positively associated with the abundance of <i>un-f-Bifidobacterium</i>. There was also a positive correlation between o-Methoxyphenyl sulfate and the gut microbiota that exhibited better immunotherapy efficacy.</p> Conclusions <p>Antibiotics weaken immunotherapy efficacy in wild-type NSCLC patients. Probiotics, regardless of duration, can restore it. For antibiotic-naive patients, taking probiotics over 15 days can improve immunotherapy efficacy. Certain probiotics, including <i>un-f-Bifidobacterium</i> and <i>Roseburia</i>, may be potential candidates for improving the efficacy of immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibiotics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月10日

查看全文
  • Wei-Chi Luo,
  • Zi-Jian Huang,
  • Shi-Qi Mei,
  • Qiu-Yi Zhang,
  • Zhi-Hong Chen,
  • Ping-Ping Chen,
  • Guo-Hua Huang,
  • Fen Wang,
  • Yu Deng,
  • Hai-Yan Tu,
  • Jin-Ji Yang,
  • Chong-Rui Xu,
  • Yan-Qing Le,
  • Jing Li,
  • Jian-Hua Chang,
  • Yi-Long Wu,
  • Qing Zhou

摘要

Background

In non-small cell lung cancer (NSCLC) patients, antibiotics impair immunotherapy efficacy, while probiotics can enhance it. The relationship between the duration of probiotics and the restoration of immunotherapy efficacy compromised by antibiotics, as well as its potential to enhance immunotherapy outcomes in antibiotic-naive patients, remains unclear. Furthermore, more probiotic types and their mechanisms for improving immunotherapy efficacy need to be identified and elucidated.

Methods

This multicenter study enrolled wild-type NSCLC patients. Clinicopathological features were recorded, focusing on antibiotic and probiotic use and duration. Baseline fecal and blood samples were collected. Gut microbiota were analyzed via 16S rRNA sequencing, and serum metabolites were analyzed through untargeted metabolomics. Flow cytometry was used to explore potential mechanisms.

Results

524 wild-type NSCLC patients were enrolled in the study, with fecal samples collected from 22 patients. Patients receiving antibiotics alone exhibited poorer PFS and OS. For those receiving antibiotics, the use of probiotics, regardless of duration, led to improved PFS and OS, which were comparable to those of patients in the No antibiotics + No probiotics group. Among the patients who did not receive antibiotics, those who were treated with probiotics for more than 15 days showed improved PFS. Patients with enriched gut microbiota in un-f-Bifidobacterium and roseburia showed better PFS. The frequency of peripheral Th cells was positively associated with the abundance of un-f-Bifidobacterium. There was also a positive correlation between o-Methoxyphenyl sulfate and the gut microbiota that exhibited better immunotherapy efficacy.

Conclusions

Antibiotics weaken immunotherapy efficacy in wild-type NSCLC patients. Probiotics, regardless of duration, can restore it. For antibiotic-naive patients, taking probiotics over 15 days can improve immunotherapy efficacy. Certain probiotics, including un-f-Bifidobacterium and Roseburia, may be potential candidates for improving the efficacy of immunotherapy.